ImProDia · raw details

Improdia is a diagnostic company that develops clusters of novel proprietary biomarkers for monitoring the immunity status of patients suffering from diseases associated with chronic inflammation. The technology enables the tracking of disease regression, recurrence and treatment response, and immunity status. The technology will help to identify patients who are most likely to benefit from a particular therapeutic treatment and to predict the occurrence of complications before they are evident. Improdia's technology has potential as a prognostic/diagnostic kit for a wide range of chronic inflammatory diseases and as a key tool for pharmaceutical companies in the development of new drugs for cancer, Alzheimer's disease, heart disease, rheumatology, and pulmonary diseases. Improdia's R&D focuses on developing a clinical prototype that can be successfully used in multi-center trials. The emphasis of the work revolves around product establishment and characterization, process standardization, and quality control validation. Improdia was established based on a project conceived in the Department of Immunology under Professor Michal Baniyash at the Hebrew University of Jerusalem.